Celldex’s CSU drug could chal­lenge a No­var­tis can­di­date af­ter PhII

Celldex Ther­a­peu­tics’ an­ti-KIT an­ti­body hit the pri­ma­ry end­point in a mid-stage test in chron­ic spon­ta­neous ur­ticaria, with some an­a­lysts de­scrib­ing the da­ta as bet­ter than …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER